

MEDIA RELEASE - COMMUNIQUE AUX MEDIAS - MEDIENMITTEILUNG

## Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

Schlieren (Zurich), Switzerland, April 23, 2009 – Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders' Meeting 2009.

The following resolutions were approved:

- the Annual Report, the Annual Financial Statements of Cytos Biotechnology Ltd and the Consolidated Financial Statements for the year 2008.
- carry forward of the gain and transfer of additional paid-in capital to free reserves.
- discharge of the members of the Board of Directors and of the Executive Board.
- extension of the authorized share capital ("genehmigtes Aktienkapital") in the amount of CHF 100,000.
- re-elections of 3 members of the Board of Directors for a further term of three years:
  - Thomas Hecht, MD, resident in Küsnacht am Rigi, German citizen
  - Jean-Yves le Cottonnec, MD, MSc (Mathematics and Statistics) and advanced degree in electronic engineering, resident in Arzier (VD), Swiss and French citizen
  - Thorlef Spickschen, Dr. rer. pol., resident in Seeheim-Jugenheim (Germany), German citizen
- re-election of PricewaterhouseCoopers Ltd as statutory auditors and group auditors for a further term of one year.
- amendments of the Articles of Incorporation based on amendments of the Swiss Code of Obligations.

The Annual Shareholders' Meeting of Cytos Biotechnology took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 58 shareholders. 1,015,454 shares or 19.3% of a total of 5,270,056 shares were represented.

### **About Cytos Biotechnology**

*Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a diversified pipeline of different Immunodrug™ candidates in various disease areas, of which five are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 133 employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).*

For further information please contact:

**Cytos Biotechnology Ltd**

Jakob Schlapbach, MBA

Chief Financial Officer

Tel.: +41 44 733 46 46

Fax: +41 44 733 47 02

e-Mail: [jakob.schlapbach@cytos.com](mailto:jakob.schlapbach@cytos.com)

Website: [www.cytos.com](http://www.cytos.com)

This foregoing press release may contain forward-looking statements that include words or phrases such as “are intended for”, “are designed to” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.